Impact of different blood group incompatibilities in kidney transplantation: a 15-year outcomes analysis from a large kidney transplant center.

Frontiers in transplantation Pub Date : 2025-11-18 eCollection Date: 2025-01-01 DOI:10.3389/frtra.2025.1690999

Dalia A Obeid, Dieter C Broering, Khalid A AlMeshari, Yaser Z Shah, Hassan A Aleid, Hadeel M AlManea, Amira M AlAbassi, Nour AlMozain, Kris Marquez, Eman A Alsaadi, Tariq Z Ali

{"title":"Impact of different blood group incompatibilities in kidney transplantation: a 15-year outcomes analysis from a large kidney transplant center.","authors":"Dalia A Obeid, Dieter C Broering, Khalid A AlMeshari, Yaser Z Shah, Hassan A Aleid, Hadeel M AlManea, Amira M AlAbassi, Nour AlMozain, Kris Marquez, Eman A Alsaadi, Tariq Z Ali","doi":"10.3389/frtra.2025.1690999","DOIUrl":null,"url":null,"abstract":"Background: While ABO-incompatible kidney transplantation (ABOiKT) has demonstrated favorable short-term outcomes, data on its long-term effects remain limited. This study evaluated the short- and long-term clinical outcomes of ABOiKT across various ABO-incompatible donor-recipient combinations.Methods: We included patients who underwent ABOiKT at our institution in 2007-2024. The outcomes assessed included 15-year data on graft, patient survival, and early AMR rates.Results: Of 239 ABOiKT cases, AMR occurred in 9.2% and was linked to longer hospitalization and higher graft failure. AMR was most frequent in B-O (20.3%) and A1-O (13.3%) transplants but no cases of AMR were observed in the recipients of kidneys from A2 donors. B to O mismatch significantly increased the risk of AMR-related graft loss. Patient survival was 99.1% at 1 year and 86.2% at 15 years and Graft survival was 92.7% and 87.5% respectively.Conclusions: Our study showed favorable outcomes of ABOiKT across different mismatch types. As the largest ABOiKT study in the Middle East with extended follow-up, our study provides important regional insights and contribute significantly to the global understanding of ABOiKT outcomes.","PeriodicalId":519976,"journal":{"name":"Frontiers in transplantation","volume":"4 ","pages":"1690999"},"PeriodicalIF":0.0000,"publicationDate":"2025-11-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12669197/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in transplantation","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3389/frtra.2025.1690999","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Background: While ABO-incompatible kidney transplantation (ABOiKT) has demonstrated favorable short-term outcomes, data on its long-term effects remain limited. This study evaluated the short- and long-term clinical outcomes of ABOiKT across various ABO-incompatible donor-recipient combinations.

Methods: We included patients who underwent ABOiKT at our institution in 2007-2024. The outcomes assessed included 15-year data on graft, patient survival, and early AMR rates.

Results: Of 239 ABOiKT cases, AMR occurred in 9.2% and was linked to longer hospitalization and higher graft failure. AMR was most frequent in B-O (20.3%) and A1-O (13.3%) transplants but no cases of AMR were observed in the recipients of kidneys from A2 donors. B to O mismatch significantly increased the risk of AMR-related graft loss. Patient survival was 99.1% at 1 year and 86.2% at 15 years and Graft survival was 92.7% and 87.5% respectively.

Conclusions: Our study showed favorable outcomes of ABOiKT across different mismatch types. As the largest ABOiKT study in the Middle East with extended follow-up, our study provides important regional insights and contribute significantly to the global understanding of ABOiKT outcomes.

Abstract Image

查看原文本刊更多论文

不同血型不相容对肾移植的影响：来自大型肾移植中心的15年结果分析。

背景：虽然abo血型不相容肾移植（ABOiKT）已显示出良好的短期结果，但其长期效果的数据仍然有限。本研究评估了ABOiKT在各种abo血型不相容的供体-受体组合中的短期和长期临床结果。方法：我们纳入了2007-2024年在我院接受ABOiKT的患者。评估的结果包括15年的移植物数据、患者生存率和早期AMR率。结果：239例ABOiKT病例中，AMR发生率为9.2%，与住院时间更长和移植物衰竭发生率更高有关。AMR在B-O（20.3%）和A1-O（13.3%）移植中最为常见，但在A2供者肾脏受体中未观察到AMR病例。B - O配错显著增加了amr相关移植物损失的风险。患者1年生存率为99.1%，15年生存率为86.2%，移植物生存率分别为92.7%和87.5%。结论：我们的研究显示ABOiKT在不同的错配类型中效果良好。作为中东地区规模最大的ABOiKT研究，我们的研究提供了重要的区域见解，并对ABOiKT结果的全球理解做出了重大贡献。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Frontiers in transplantation

自引率

0.00%

发文量